Concerns over the safety of the U.S. drug supply were recharged as Glenmark Pharmaceuticals initiated the recall all of nearly 2,000 lots of its Zantac generics from the U.S. market because they may contain elevated levels of a possible cancer-causing impurity.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,